-+ 0.00%
-+ 0.00%
-+ 0.00%

GeneDx Expands Commercial Expansion Into Inborn Errors Of Immunity

Benzinga·04/03/2025 12:13:30
Listen to the news

Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and biopharma partners to accelerate the path to treatment for patients